

Recommendations

PCV13 and 23PPV are recommended but not funded for the following individuals:

immune-competent adults (aged 18 years and older) at increased risk of pneumococcal disease or its complications because of chronic illness (eg, chronic heart, renal, liver or pulmonary disease, diabetes or alcohol dependency)

- immunocompromised adults at increased risk of pneumococcal disease (eg, those with nephrotic syndrome, multiple myeloma, lymphoma and Hodgkin's disease)
- individuals of any age who have had one episode of IPD
- smokers.

For those individuals who choose to purchase PCV13 and 23PPV vaccines, providers may follow the age-appropriate schedules in [Table 16.4](#) and [Table 16.5](#).

Adults aged 65 years and older with no other risk factors Give one dose of PCV13 followed at least eight weeks later with 23PPV (not funded).

Table 16.5: Extended pneumococcal immunisation for adults aged 18 years and older – funded PCV13 and 23PPV indications and schedules

PCV13 (Prevenar 13) and 23PPV (Pneumovax 23) are funded for (re)vaccination of patients:

- with HIV infection
- who are pre- or post-HSCT^a or chemotherapy^a
- who are pre- or post-splenectomy or with functional asplenia
- who are pre- or post-solid organ transplant
- undergoing renal dialysis
- with complement deficiency (acquired or inherited)
- with cochlear implants, intracranial shunts^b or cerebrospinal fluid leaks^b
- with primary immunodeficiency.

Age at diagnosis	Vaccine	Recommended vaccine schedule
≥18 years	PCV13	Give one dose of PCV13 ^c
	23PPV	Give a maximum of 3 doses of 23PPV in a lifetime, a minimum of 5 years apart. The first 23PPV dose is given at least 8 weeks after PCV13, the 2nd a minimum of 5 years later, and the 3rd dose at age ≥65 years.

a. PCV13 is funded pre- or post-HSCT or chemotherapy. 23PPV is only funded post HSCT or chemotherapy.

b. Only PCV13 is funded for these indications.

Version 2: Communications to General Practice – COPD WW Programme			
Created	08/03/2024	Last Updated	10am 27/02/2026

If 23PPV has already been given (prior to any doses of PCV13) to adults aged 18 years and older, wait at least 1 year before administering PCV13.

Chantel Punter | Immunisation Education Facilitator/0800

T +64 272532198

imacetadmin@auckland.ac.nz | www.covid.immune.org.nz

Version 2: Communications to General Practice – COPD WW Programme			
Created	08/03/2024	Last Updated	10am 27/02/2026